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Objective.—To review the challenges and potential solutions in treatment options for quality migraine care in adult
patients who are under or uninsured.
Background.—The Affordable Care Act has improved access to health care for many; however, those who are under-
served continue to face treatment disparities and have inadequate access to appropriate migraine management.
Methods.—This manuscript is the second of a 2-part narrative review which was performed after a series of discussions
within the Underserved Populations in Headache Medicine Special Interest Section meetings of the American Headache Soci-
ety. Literature was reviewed for key concepts underpinning conceptual boundaries and a broad overview of the subject matter.
Published guidelines, state-specific Medicaid websites, headache quality measurement sets, literature review, and expert opinion
were used to tailor suggested treatment options and therapeutic strategies. In this second part of our narrative review, we
explored migraine care strategies and considerations for underserved and vulnerable adult populations with migraine.
Results.—Although common, migraine remains untreated, particularly among those of low socioeconomic status. Low
socioeconomic status may play an important role in the disease progression, prescription of hazardous medications such as
opioids, outcomes, and quality of life of patients with migraine and other headache disorders. There are some evidence-
based and guideline supported treatment options available at low cost that include prescription medications and supple-
ments, though approved devices are costly. Resources available online and simple nonpharmacological strategies may be
particularly useful in the underserved migraine population.
Conclusions.—We identified and discussed migraine treatment barriers that affect underserved populations in the US
and summarized practical, cost-effective strategies to surmount them. However, more research is needed to identify the
best cost-effective measures for migraine management in underserved and vulnerable patients who are uninsured or
underinsured.
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INTRODUCTION
In part one of this review, we described the
methodology which led to the execution of this nar-
rative review by the Underserved Populations in
Headache Medicine special interest section of the
American Headache Society, followed by an explo-
ration of the epidemiology of the underserved popu-
lation with migraine as well as the challenges in
managing patients who are at a disadvantage in this
context. In part two, using the same narrative meth-
odology we specifically address management consid-
erations of the underserved population with
migraine. There are three approaches generally con-
sidered in migraine treatment. These approaches
include abortive (acute), prophylactic (preventive),
and nonpharmacological (ie, lifestyle, behavioral
changes) treatments and modalities. In this section,
we will explore each therapeutic group with special
considerations and suggestions for underserved, vul-
nerable, and underinsured adult populations.
Treatment Considerations and Options.—Acute
(Abortive) Treatment of Migraine in the Under-
served Population.—The goals of acute migraine
therapy in the underserved population are the same
as the goals for the general population at large who
suffer with migraine (Table 1).1 There are several
challenges in meeting these goals in the under-
served as outlined in part one of this manuscript.
An important consideration for populations with
migraine who have low socioeconomic status is the
risk of developing chronic migraine in association
with medication overuse that can occur with acute
medications. At least two-thirds of people with
medication overuse headache (MOH) have
migraine as their primary headache disorder.2 The
sociodemographic profile of the MOH population
with chronic migraine is characterized by a higher
proportion of women, a lower education level, and
a higher level of unemployment as compared to
those with episodic migraine.3
Most all of the group 1 (proven, pronounced sta-
tistical and clinical benefit) medications recom-
mended in the 2000 AAN practice parameter and
the Level A (established as effective based on avail-
able evidence) medications listed by the American
Headache Society Guidelines Committee are sub-
stances that can be associated with MOH in suscep-
tible persons.4 Prochlorperazine IV (Group 1, Level
B) is the only exception.1,5 Although relatively inex-
pensive medications, butalbital-containing products
and opioids may lead to the development of MOH
in the medically underserved as readily as in the
general migraine population. Opioid use has been
associated with lower annual household income
when compared to nonusers and opioid users are
less likely to be currently married or employed.6 It
is possible that increased use of opioids in the under-
served population particularly elevates the risk of
MOH. In addition, opioids and butalbital-containing
medications may be more forceful drivers of MOH.4
In our experience, unlike triptans, practitioners pre-
scribing opioids and butalbital-containing compounds
Table 1.—2000 AAN Practice Parameter: Acute Treatment
Goals1
1. Treat attacks rapidly and consistently without recurrence.
2. Restore the patient’s ability to function.
3. Minimize the use of back-up and rescue medicines.
4. Optimize self-care and reduce subsequent use of
resources.
5. Be cost effective for overall management.
6. Have minimal or no adverse events.
Conflict of Interest: Larry Charleston IV: serves as consul-
tant, an advisory board member, or has received honoraria
from Alder, and is a panelist for Amgen Health Equity
Summit. Jeffrey Royce: is a speaker for Allergan, Pernix,
Avanir, Depomed, Promius Pharma, and Teva and has
received research support from Avanir. Teshamae Dr.
Monteith: reports personal fees from advisory work for Eli
Lilly, Allergan, Supernus, Electrocore and Teva pharma-
ceuticals outside the reported work. She also received an
educational grant from Allergan and did not receive per-
sonal fees. Susan W. Broner: None. Hope L. O’Brien: is a
speaker for Avanir Pharmaceuticals and Amgen and is on
the advisory board for Allergan, has received royalties for
written contributions published in Up-to-Date, an on-line
medical reference, and Turner/White communications. Sal-
vador L. Manrriquez: None. Matthew S. Robbins: his insti-
tution has received research support from eNeura; he
serves in editorial capacities for Headache and Current
Pain and Headache Reports and has received book royal-
ties from Wiley. Monteith: reports personal fees from advi-
sory work for Eli Lilly, Allergan, Supernus, Electrocore
and Teva pharmaceuticals outside the reported work. She
also received an educational grant from Allergan and did
not receive personal fees.
634 May 2018
typically do not face quantity limits, which may lead
to more frequent use and place such patients at a
higher risk of medication overuse. Therefore, the
use of butalbital-containing products and opioids
should be limited or avoided in the underserved
with migraine.
Similar to the general population, patients in
underserved and vulnerable populations with
migraine need a formal management plan in which
appropriate therapeutic goals and realistic patient
expectations are set. Potential barriers to manage-
ment plans in underserved/vulnerable populations
may include a lack of formal education and low lit-
eracy. Persons with less education may be more
concrete in their thinking operations and may have
trouble thinking beyond the current state to plan
for future events.7 It is important to ensure under-
standing of the goal(s) of successful abortive treat-
ment. These goals may include decreasing and
eliminating the use of poorly tolerated, ineffective
or unwanted acute medications. Thus, clinical
guidelines may provide practitioners with a good
starting point to initiate appropriate treatment
options. Another goal of an abortive plan may be
to reduce the management of nonemergent head-
ache attacks in the emergency department (ED).8
One multicenter study has shown that opioids are
ordered for acute migraine treatment in 12.3% of
academic medical center visits, 40.9% of urban ED
visits, and 68.6% of community ED visits.9 ED
management often includes nonmigraine specific
medications and opioids.
Table 2.—Acute Medications for Migraine Covered by Nebraska Medicaid1,5,11-14
Acute
medication
Formulation/
strength
Preferred
drug
Prior
authorization
required
Medicaid state
maximum allowable
cost
Level A/Group I
Ibuprofen 600, 800 mg tabs Preferred $0.04821
$0.05695
Naproxen 375, 500 mg tabs Preferred $0.05360
$0.06499
Diclofenac 50 mg tab Preferred $0.27500
Diclofenac 50 mg powder pack Nonpreferred PA required N/A
Sumatriptan 50, 100 mg tabs Preferred $0.69182
$0.71020
Rizatriptan 5, 10 mg tabs Preferred $0.96033
$1.26038
Rizatriptan 5, 10 mg ODT Preferred $1.56000
$1.75647
Level B/Group II
Flurbiprofen 50, 100 mg tabs Preferred $0.43027
Ketoprofen 50, 75 mg tabs Nonpreferred $0.38605
$0.49982
Codeine/APAP 30/300 mg tab Preferred $0.50960
Promethazine 25 mg suppository Preferred $8.74317
Uncategorized
Baclofen 10 mg tab Preferred $0.20932
Prednisone 10, 20 mg tabs Preferred $0.15689
$0.18760
Dexamethasone 4 mg tab N/A N/A N/A
Prochlorperazine 5, 10 mg tabs Preferred $0.06700
$0.07370
Metoclopramide 10 mg tab Preferred $0.04020
Haloperidol 1, 2, 5 mg tabs Preferred $0.38860, $0.54873, $0.83951
Promethazine 25 mg tab Preferred $7.30639
ODT, orally disintegrating tablet. https://druglookup.fhsc.com/.
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The 2000 AAN practice parameter for migraine
recommends meeting the goal of acute manage-
ment using migraine specific agents (triptans and
DHE) for patients with moderate to severe
migraine or poor non steroidal anti-inflammatory
drug (NSAID) responders.1 These medications
have proven efficacy. Unfortunately, some may cost
in excess of $12 per dose and are strictly limited in
monthly quantity on many Medicaid plans.10 Oral
NSAIDs and combination analgesics with caffeine
are considered reasonable first-line treatment
choices for mild to moderate migraine attacks or
severe attacks that have previously responded to
NSAIDs. Many generic NSAIDs are covered on
Medicaid plans. Ibuprofen and naproxen are often
included in reduced cost cash pay formularies (see
Table 2). Acetaminophen, which was considered
clinically ineffective per the 2000 AAN practice
parameter, has been elevated to a Level A for non-
incapacitating attacks in more recent AHS guide-
lines.5 Acetaminophen, in combination with
acetylsalicylic acid and caffeine, may be more effec-
tive in severe migraine headache attacks.15
Gleaning from the list of medications in Group
2 (moderate statistical and clinical benefit) and Level
B (probably effective) are the NSAIDs flurbiprofen
PO, ketoprofen PO, and ketorolac IV/IM. Dopa-
mine antagonists prochlorperazine IV/IM, chlor-
promazine IV, metoclopramide IV, and
prochlorperazine 25 mg PR are also Group 2 and
Level B agents.1,5 These are abortive medications
with low risk of causing MOH. Attempting oral use
of dopamine antagonists alone or in combination for
analgesia has not been rigorously studied but may
be reasonable as they often appear on low cost for-
mularies and have antiemetic effects.16,17 Prometha-
zine has the lowest risk of extrapyramidal side
effects, as it is a weak dopamine antagonist which
has strong anticholinergic and antihistaminic effects,
though studies specifically in migraine are lacking.
Two antihistamines may be used as adjuvant
medications to dopamine antagonists to prevent aka-
thisia. Hydroxyzine possesses anxiolytic qualities and
has been studied for use in pain alone and with
DHE in migraine.18,19 Diphenhydramine is fre-
quently used as a parenteral adjunct for migraine
treatment in the ED, though study results have been
mixed.11,20-24 Neither drug is listed in the AHS
guidelines or the 2000 AAN practice parameter.
Finally, baclofen is a GABA receptor agonist
used to treat spasticity. A few studies have been
conducted using it in the treatment of migraine or
pain.25-27 Baclofen is often listed on the low cost
cash formularies and may be considered as an acute
medication for migraine in our experience and in
the limited literature reports. Again, neither the
AAN practice parameter nor the AHS guidelines
evaluated this medication because of a low quality
of evidence (see Table 2).
Prophylactic (Preventive) Treatment of Migraine in
the Underserved Population.—Migraine is under-
treated with prophylactic medication in the US
population as a whole. Of those who receive pro-
phylaxis, prophylactic medications with low quality
evidence are prescribed to just over one-fourth of
patients with migraine.28 In fact, it is almost twice
as likely that people with migraine will only receive
prophylactic medications with low-quality evidence
as it is that they will receive prophylactic medica-
tions with only high-quality evidence.28 We will
review the goals of prophylactic or preventive
agents in migraine, the considerations for their use,
and tips to optimizing preventive therapies in this
section of the manuscript. Some natural supple-
ments and complementary agents have high-level
evidence as migraine prophylactic agents and they
will be discussed in a subsequent section.
The goals of preventive or prophylactic agents
usually include one or more of the following: (1)
reduce frequency of headache attacks, (2) reduce
duration of headache attacks, (3) reduce the num-
ber of days of headache, (4) reduce the use/need of
abortive medications, and (5) improve quality of
life.12,29 Prophylaxis may also help to reduce the
associated symptoms of migraine as well as the
interictal burden. Prevention should be offered to
those with migraine reporting 6 or more headache
days per month, 4 or more headache days with at
least some impairment, or 3 or more headache days
with severe impairment or requiring bed rest, and
should be considered in patients with 4 or 5
migraine days per month with normal functioning,
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3 migraine days with some impairment, or 2
migraine days with severe impairment.29 Patients
should be informed that it may take approximately
12 weeks at an effective, appropriate dose of the
prophylactic agent before results are seen and goals
are realized. Counseling of prophylaxis may be very
important to maximize adherence and avoid early
prophylactic discontinuation (ie, after 2-3 weeks of
taking agent) due to “lack of response” as an ade-
quate trial is necessary. Initiation of therapies at
the lowest effective dose is recommended with slow
titration until clinical benefits are realized without
untoward effects or limited by untoward effects.
Overuse of abortive medications should be avoided.
Comorbid conditions and coexisting illnesses should
be considered when prescribing medications. Head-
ache diaries or calendars may be very helpful in
patient management and are available at very little
or no cost to patients. As mentioned previously,
these recommendations are time consuming to
implement in the clinical setting and underserved
populations with migraine may not be well posi-
tioned to receive them because of poor access to
care or low educational levels.
The American Academy of Neurology Head-
ache Quality Measure Set (AAN-HQMS) recom-
mended guideline prophylactic medications for
episodic migraine: level A are divalproex/sodium
valproate 400-1500 mg/daily, topiramate 25-200 mg,
propranolol 80-240 mg, metoprolol 47.5-200 mg, and
timolol 10-15 mg BID. Frovatriptan can be tried for
short-term prophylaxis of menstrual related migraine
(MRM).12 Although frovatriptan has level A evi-
dence for the prophylactic treatment of MRM, other
triptans (eg, zolmitriptan, sumatriptan, rizatriptan)
have also been shown to be effective. A generic or
lower cost triptan (eg, naratriptan 1 mg/d for 6 days,
or zolmitriptan 2.5 mg BID/TID for 5 days (level
B), sumatriptan 25 mg TID for 5 days) may provide
an effective low cost alternative for the prophylaxis
of MRM; however, such use often exhausts the
monthly triptan allotment by insurance coverage
including Medicaid.30,31
Level B prophylactic recommendations include
amitriptyline 25-150 mg/daily, venlafaxine 75-225 mg,
atenolol 100 mg daily, nadolol, NSAIDs (fenoprofen
200-600 mg, ibuprofen 200 mg BID, ketoprofen 50 mg
TID, naproxen 250-500 mg daily, naproxen sodium
550 mg BID) histamine 1-10 ng subcutaneously twice
a week and bisoprolol 5-10 mg daily.12 NSAIDs may
have a protective effect when used 5-10 days per
month; however, taken 10 days per month, NSAIDs
may increase the risk of medication overuse head-
ache.4,12 State-specific Medicaid program websites
Table 3.—High Quality (Level A or B) Prophylactic Medications for Migraine Covered by Nebraska’s Medicaid12-14
Prophylactic
medications
Formulation/
strength
Preferred
drug
Prior authorization
required
Medicaid state maximum
allowable cost
Level A
Divalproex sodium 250 mg tab N/A N/A $0.09380
Topiramate 25 mg tab Preferred N/A $0.03815
Propranolol 80 mg tab Preferred N/A $0.50649
Metoprolol succ ER 50 mg tab Preferred N/A $0.37520
Timolol maleate 10 mg tab Nonpreferred N/A N/A
Bisoprolol fumarate 5 mg tab Nonpreferred PA required $0.44533
Level B
Amitriptyline HCl 25 mg tab N/A N/A $0.32160
Venlafaxine HCl 75 mg tab Preferred N/A $0.25366
Atenolol 100 mg tab Preferred N/A $0.03279
Nadolol 40 mg tab Nonpreferred PA required $2.21100
Ibuprofen 200 mg caplet Preferred N/A $0.02500
Ketoprofen 50 mg capsule Nonpreferred PA required $0.38605
Naproxen 250 mg tab Preferred N/A $0.04020
Naproxen sodium 550 mg tab Nonpreferred PA required $2.12179
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can be helpful for identifying low cost, coverage sta-
tus, and other useful information about high quality
prophylactic medications for underinsured within
individual states12-14 (see Table 3).
NATURAL SUPPLEMENTS/
NUTRACEUTICALS
Several supplements are used to reduce the fre-
quency and associated symptoms of migraine. Some
of these may be prescribed and others purchased
over the counter. Evidenced-based guidelines rate
magnesium, riboflavin, and feverfew as probably
effective while co-enzyme Q10 is rated as possibly
effective.13 Petasites, or Butterbur, has been rated
as effective, however, there is current controversy
over its safety. It is often falsely believed that natu-
ral supplements are without side effects; however,
this is not always the case and requires counseling
to patients in the same manner as prescription pre-
ventive therapies. We will explore some of the uses
as well as potential adverse effects of natural sup-
plement use in migraine.
Magnesium may be particularly effective for
patients with migraine aura and those with men-
strual migraines.31-34 Different formulations exist
but the chelated forms are better tolerated. Magne-
sium citrate has been shown to be more bioavail-
able than magnesium oxide.35 Magnesium glycinate
also appears to be highly bioavailable. The recom-
mended doses are 400-600 mg daily depending on
tolerability.36,37 Side effects include softening of
stool or diarrhea.
Several studies support use of riboflavin (vitamin
B2) for migraine prevention. The recommended
doses are up to 400 mg a day in adults. Side effects
include bright yellow discoloration of the urine, fre-
quent urination and less commonly diarrhea.38
Although preparations of feverfew vary widely,
MIG-99, a specific feverfew CO2-extract, has been
shown to be safe and effective at 6.25 mg TID.
Side effects may include gastrointestinal upset,
mouth ulcers and a “post-feverfew syndrome of
joint aches.”39,40 Dosing of co-enzyme Q10 for
adults is 300 mg once a day. Side effects, although
appearing rarely, can include gastrointestinal upset
and skin allergies.41,42
Although the level of evidence varies, other
natural supplements such a thioctic acid 600 mg/day
(for migraine prophylaxis), vitamin E 400 IU for 5
days (for menstrual migraine prophylaxis), and
ginko biloba (for prophylaxis of migraine aura)
may be helpful in migraine and its associated symp-
toms in select populations.43-47
Cost may also be a concern with supplements
since they are not generally covered by insurers. For
example, Co-enzyme Q10 and Butterbur can be
costly. However, magnesium, riboflavin, and feverfew
are readily purchased in a health food store or phar-
macy and are relatively inexpensive. Vitamin E use
for menstrual or menstrual-related migraine as
described above is also relatively inexpensive.
Patients may be encouraged to browse online for the
best value (price, quantity, and quality). It is impor-
tant to note that the US Food and Drug Administra-
tion does not regulate natural supplements.
CHRONIC MIGRAINE PROPHYLAXIS
Expert consensus supports the use of migraine
preventive strategies considered effective for epi-
sodic migraine in chronic migraine. Topiramate has
also been shown to be effective specifically for
chronic migraine.48 Topiramate is available in a
generic form in the US. Currently, onabotulinum-
toxinA is effective and the only US-FDA approved
treatment for chronic migraine.49-53 It has been
shown to be cost-effective in patients with chronic
migraine and may decrease ED utilization and hos-
pitalizations. Treatment with onabotulinumtoxinA
may result in overall health cost savings and
increase quality of life for patients with chronic
migraine.54,55 Although we have found this treat-
ment to be partially covered in some Medicaid pro-
grams, the proportion that remains for patients to
cover may be an expense that presents an economic
barrier for patients to receive treatment. Insurance
authorization and a step-wise approach are required
for most insurances to limit cost despite the lack of
evidence-based justification for this strategy. How-
ever, the reduction in headache-related health care
utilization among adults with chronic migraine
treated with onabtulinumtoxinA as compared to
oral migraine prophylactic medications suggest a
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potential benefit from earlier initiation.56 In addi-
tion, this therapy does not feature any concerns
about adherence because of practitioner administra-
tion and the long therapeutic benefit over a 3
month period.
Devices.—Newer devices and products that have
demonstrated some evidence for efficacy in head-
ache disorders are emerging. Two devices have
recently been FDA approved and have come to
market for the care of migraine in the US; a trans-
cutaneous supraorbital neurostimulation device,
CefalyV
R
(Cefaly US, Inc., Wilton, CT, USA), and a
single pulse transcranial magnetic stimulator,
SpringTMSV
R
(eNeura, Inc., Baltimore, MD,
USA).57-60 However, their costs may be prohibitive
in this population. The Cefaly device was the first
FDA approved device for the prophylactic treat-
ment of migraine and is now approved for acute
attack treatment as well. However, this device and
its accessories are not covered by most insurances
and out-of-pocket cost are usually around $375.00
USD. The SpringTMS device has been FDA
approved for the acute treatment of migraine with
aura and for migraine prophylaxis.61 The cost to
rent this device is $250.00 USD per month billed in
3 month increments and an initial shipping fee of
$50.00 USD. In our clinical practice, we have not
found these costs to be routinely covered by insur-
ances. To the authors’ knowledge, neither device
company currently has programs in place to help
care for underinsured populations.
Low/Noncost Nonpharmacological Treatment
Modalities.—Migraine may be best managed in a
multimodal fashion.62,63 In addition to medication,
nonpharmacological approaches can be employed.64
These modalities include lifestyle changes, stress man-
agement, use of heat or cold, and addressing migraine
comorbidities that contribute to its chronification.63,65
Information about complementary treatments as well
as methods for addressing these factors can be low-
cost or free and include patient education as well as
resources patients can access themselves. Finally, the
engagement of other health professionals can be use-
ful in addressing the burden of migraine.62
Other Alternative Treatments.—Acutely, many
patients find heat or cold packs, a hot shower, or a
combination of these beneficial in dampening down
the pain of migraine or tension-type headache.66
Some patients find topical treatments such as herbal
balms with small amounts of menthol or camphor
(one of the main components of Tanacetum parthe-
nium) applied to the temples, forehead, or base of
the neck helpful.67,68 Inhalation of lavender essential
oil for 15 minutes may be helpful for some patients
with migraine.69 Deep relaxation, diaphragmatic
breathing, and cognitive behavioral techniques to
adapt behavioral responses to pain can also be use-
ful.70,71 Mindfulness and meditation may also be
helpful.65,72,73 Teaching these techniques is simple
and there are multiple online resources for down-
loadable exercises easily found via internet search
engines (eg, search term5 “downloadable deep
relaxation and breathing techniques”). Avoidance of
migraine triggers is also recommended.74 Trigger
management apps, online educational resources, and
patient support organizations may be considered to
supplement headache management. Most public
libraries have computers and Internet services that
can be readily accessed by patients who do not have
computers or Internet access at home.
Lifestyle and Other Health Factors.—Chronification
of migraine has been associated with stressful life
events, medication overuse, obesity, sleep distur-
bance, depression, and caffeine overuse.75,76 Modify-
ing these risk factors can be as important as
medication initiatives and can directly improve
patient outcomes. Additionally, sleep, diet, exercise,
and hydration all seem to play a role in migraine.
Limited resources can be a barrier to addressing
these but patient education and engagement of other
health care professionals can be employed at low or
no cost. Table 3 outlines many of these aspects and
contains simple recommendations for the patient
that can be readily integrated into patient care.
OTHER CONDITIONS AND
CONSIDERATIONS
Medication Overuse.—Educating patients about
medication overuse and its contribution to head-
ache chronification should be considered a founda-
tion for discussing acute treatments. Limiting acute
treatments to 2-3 days per week or less can be the
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first step toward improving outcomes and will
enhance the patient’s response to preventatives.
Depression.—Identification of depression histori-
cally has been time consuming leading to under
diagnosis of this disorder.77 However, a simple self-
administered screening tool such as the PHQ-9 can
be used to identify those with depression which
may be useful in the management of underserved
populations who have limited access to behavioral
health professionals.77 In addition to anti-
depressant medications that can dovetail as head-
ache prevention agents, referral to a clinic social
worker may provide the additional needed therapy
at low or no cost.
Use of Other Healthcare Professionals.—Primary
care physicians most commonly treat patients with
migraine, although universal awareness of migraine
guidelines is lacking.78 Patients should be referred to
neurologists when migraine is refractory to treat-
ments, associated with a high degree of disability, or
have atypical symptoms. Referral to headache subspe-
cialists or integrative headache care centers are often
effective for chronic or treatment refractory migraine
cases,62 but such specialists are often aggregated in
selected geographic areas79 or lacking in many states
entirely.80 In a clinic setting, referrals to in-house
healthcare professionals can be employed to reduce
other comorbidities. Many Medicaid clinics have a
Table 4.—Low Cost Behavioral and Lifestyle Recommendations for Headache Management
Lifestyle factor Recommendation References81-89
Hydration Drink 6-8 cups of water a day W€ober C, W€ober-Bing€ol C. Triggers of migraine and
tension-type headache. Handbook of Clinical Neurology
Headache. New York, NY: Elsevier BV; 2010:161-172.
Sleep Encourage good sleep hygiene and a
regular waking time daily
Rasmussen BK. Migraine and tension-type headache in a
general population: Precipitating factors, hormones,
sleep patterns and relation to lifestyle. Pain. 1993;53:65-
72.
Guidetti V. Sleep and headaches. In: Wuidetti V, Sillan-
paa M, Russell G, Winner P, eds. Headache and
Migraine in Childhood and Adolescence. London:
Martin Dunitz; 2002:417-431.
Caffeine Limit caffeine to 8 oz a day Tepper SJ, Tepper DE. Preventative treatment of epi-
sodic migraine. The Cleveland Clinic Manual of Headache
Therapy. New York, NY: Springer; 2014:161-178.
Addicott MA, Yang LL, Peiffer AM, et al. The effect of
daily caffeine use on cerebral blood flow: How much caf-
feine can we tolerate? Hum Brain Mapp. 2009;30:3102-3114.
Exercise Regular exercise of at least 3 times a
week for 20 minutes or more. Free
or low-cost gyms are in many cities
and towns. Online exercise programs
are also available.
Varkey E, Cider A, Carlsson J, Linde M. A study to eval-
uate the feasibility of an aerobic exercise program in
patients with migraine. Headache. 2009;49:563-570.
Diet Eat meals on regular basis. Do not
skip meals. Avoid processed foods.
Avoid their known triggers. Refer to
nutritionist for help in weight loss.
Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors
associated with the onset and remission of chronic daily
headache in a population-based study. Pain.
2003;106:81-89.
Stress reduction Encourage enhancing activities ranging
from exercise/sports to meditation
and mindfulness. Cognitive behav-
ioral techniques can also be useful.
Online resources exist. Referral to
clinic social worker.
Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch
KM. Comorbidity of migraine and depression: Investi-
gating potential etiology and prognosis. Neurology.
2003;60:1308-1312.
Medication overuse Discuss limits on acute treatments to
no more than 2-3 days a week.
Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton
RB. Transformed migraine and medication overuse in a
tertiary headache centre - Clinical characteristics and
treatment outcomes. Cephalalgia. 2004;24:483-490.
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nutritionist consultation service. Using this resource
can help patients in weight reduction and in learning
healthy eating habits. Additionally, clinic social work-
ers can help in addressing mood disorders, teach cog-
nitive behavioral techniques and other coping
strategies to deal with pain as well as to reduce stress.
They also can be a referral source for help in other
areas of the patient’s life to reduce stress, such as city
or state legal or housing resources and protective serv-
ices (Table 4). Given that temporomandibular disor-
ders (TMD) are comorbid with migraine and are a
risk factor for migraine progression,90-97 it may be
helpful if people with migraine and comorbid TMD
are referred to a dentist trained in orofacial pain to
manage the TMD aspect of the patient’s pain.95
Adherence.—Studies investigating adherence to
migraine management are limited but increasing in
recent years; it is a major topic of concern for the
underserved with migraine. In reviewing the literature,
description of adherence has been either vague or
relied on self-report, and there has been no recommen-
dation on how to improve adherence in patients with
recurrent migraine. Ramsey et al published a system-
atic review that showed overall compliance to treat-
ment, including those considered nonpharmacological,
ranged from 25 to 95%, but there is little demographic
information that addresses or explains these differ-
ences.98 One study showed no significant difference in
medication compliance between African American
and Caucasian patients with migraine.99 However,
African Americans and young patients were less likely
to return for follow-up appointments. In the same
study, socioeconomic status influenced adherence
among Caucasians but not among African Americans.
There does appear to be specific management recom-
mendations where patients are likely to be adherent,
such as, once daily dosing over twice daily dosing100
and the use of a multidisciplinary approach with fre-
quent encounters between provider and patient.101 Fur-
thermore, those who practice regular aerobic exercise
tend to adhere more than those who are instructed on
healthy habits and practice relaxation techniques.101 In
general, adherence remains a concern for patients with
migraine as those who adhere with consistent manage-
ment, whether pharmaceutical, behavioral, or lifestyle
modification, tend to have overall improvement of
headache related outcomes (lower headache frequency
and disability scores).63,102
SUMMARY AND GENERAL APPROACH
TO THE UNDERSERVED POPULATION
In summary, multiple barriers exist in providing
optimal headache care to underinsured, uninsured
and Medicaid populations. Greater awareness and a
systematic approach may reduce the impact of the
headache burden, which disproportionately afflicts
underserved communities.
There are several options to optimize migraine care
in adult patients who are uninsured or underinsured.
This manuscript examines some potential nonopioid
solutions to comprehensive care for underserved popu-
lations, however, may not be all-inclusive. Although
opioids and butalbital-containing compounds are often
covered by Medicaid or offered at a very low cost for
patients to receive, practitioners should avoid them as
much as possible in this population. Opioid use for
migraine is associated with more severe headache-
related disability, symptomology, comorbidities
(depression, anxiety, and cardiovascular disease and
events) and greater need to see healthcare providers.6
Opioids are not a substitute for a comprehensive head-
ache treatment plan. Caution is also advised with the
use of butalbital-containing medications as these combi-
nation medications can lead to medication overuse
headache with only 5 days of use per month for 3
months.103 Providers are encouraged to actively seek
safer alternatives. Counseling, abortive therapies with
limits, prophylaxis, and nonpharmacological modalities
as appropriate may be the constituents of a comprehen-
sive migraine treatment plan.
Finally, newer products demonstrating efficacy
and safety in the treatment of migraine and other
headache disorders are emerging, including for the
first time biological therapies. Monoclonal anti-
bodies to calcitonin gene-related peptide and its
receptor appear to be a promising preventive treat-
ment for migraine and chronic migraine104,105 and
are likely to come to the market in 2018. In an
analogous situation with another neurological disor-
der, the US has witnessed increased costs with
disease-modifying therapies (DMT) for the treat-
ment of multiple sclerosis. DMT costs have
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skyrocketed beyond inflation over the last several
years and are currently 2-3 times higher in the US
than in other comparable countries, generating con-
cern within the neurology community.106,107 It is
our hope that technological, pharmaceutical, and
other industries consider as well as implement plans
to make their emerging headache therapies includ-
ing biological drugs and devices accessible to
underserved and underinsured populations.
Limitations.—There are inherent limitations in this
2-part narrative review. The authors undertook this
review because of the paucity of research on this partic-
ular topic and, therefore, may be subject to bias. This
manuscript does not address all social determinants
that are likely to play a role in the headache health of
underserved and underinsured populations (eg, cultural
considerations, environments/community, transporta-
tion, etc). A multicollaborative systematic approach
may be needed to address these concerns of under-
served and vulnerable populations. Although many of
our recommendations are derived from recently pub-
lished guidelines, some are not and the body of evi-
dence varies. Quality headache care is needed for these
vulnerable populations. In addition, telemedicine is
becoming more widely used for neurological conditions
and may be a mechanism to address barriers to care,
provide medical consultation, and may provide cost-
saving alternatives for underserved and underinsured
populations in headache medicine.108,109
More research is needed to explore mecha-
nisms to improve quality care, decrease gaps in
care, investigate low cost therapies, balance cost,
and policy with medical innovation, and address
headache care inequities of underserved, vulnera-
ble, underinsured, and uninsured populations.
CONCLUSION
Migraine is a common, undertreated, and under-
diagnosed disorder that is even more prevalent and
may have a worse course among those with a low
socioeconomic status. Moreover, a number of individ-
ual, societal and healthcare barriers negatively influ-
ence underinsured and uninsured migraine sufferers.
Low socioeconomic status may play an important
role in the disease progression, characteristics, out-
come, and quality of life of patients with migraine
and other headache disorders. Research is needed to
identify the best cost-effective measures for migraine
management especially during this period of rapidly
changing healthcare policies and medical innovation.
Although cost remains an issue, conscientious com-
prehensive headache treatment plans are valuable,
available, and may be needed to improve patient out-
comes in the underinsured and uninsured.
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